Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - midazolam, quantity: 5 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; sodium chloride; water for injections; nitrogen - iv as an agent for conscious sedation prior to short surgical, diagnostic, therapeutic or endoscopic procedures, such as bronchoscopy, gastroscopy, cystoscopy, coronary angiography and cardiac catheterisation, either alone or in conjunction with a narcotic; iv for induction of anaesthesia, preliminary to administration of other anaesthetic agents. with the use of a narcotic premedicant, induction of anaesthesia can be attained with a narrower dose range and in a shorter period of time. iv for sedation in intensive care units; intermittent administration or continuous infusion. im for preoperative sedation (induction of sleepiness or drowsiness and relief of apprehension) and to impair memory of perioperative events.

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - ketamine hydrochloride 115.34 mg/ml equivalent to ketamine 100 mg/ml - solution for injection - 100 mg/ml - active: ketamine hydrochloride 115.34 mg/ml equivalent to ketamine 100 mg/ml excipient: nitrogen water for injection - ketamine-baxter is recommended: 1. as the sole anaesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation. ketamine-baxter is best suited for short procedures and it can be used with additional doses, for longer procedures; 2. for the induction of anaesthesia prior to the administration of other general anaesthetic agents; 3. to supplement low-potency agents, such as nitrous oxide.

Singapore - English - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - furosemide - injection, solution - furosemide 20 mg/2 ml

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - furosemide 10mg - solution for injection - 10 mg/ml - active: furosemide 10mg excipient: hydrochloric acid sodium hydroxide ph adjustment sodium chloride sodium hydroxide water for injection - furosemide-baxter injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. furosemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations.

European Union - English - EMA (European Medicines Agency)

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastic agents - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5.1).pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.1).

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol; nitrogen - bortezomib baxter, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,bortezomib baxter, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,bortezomib baxter is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.,bortezomib baxter in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - vancomycin hydrochloride, quantity: 1025.2 mg - injection, powder for - excipient ingredients: hydrochloric acid; sodium hydroxide - vancomycin baxter is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins.,vancomycin baxter is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly.,vancomycin baxter is effective alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (e.g., s. faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin baxter is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by s. epidermidis or diphtheroids.,the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures.,specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin.,vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - vancomycin hydrochloride, quantity: 512.6 mg - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid - vancomycin baxter is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins.,vancomycin baxter is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly.,vancomycin baxter is effective alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (e.g., s. faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin baxter is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by s. epidermidis or diphtheroids.,the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures.,specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin.,vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - irinotecan hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - chlorhexidine acetate, quantity: 5 mg/ml - solution, irrigation - excipient ingredients: cetrimide; glacial acetic acid; water for injections; methylene blue - chlorhexidine acetate (0.5 %) antiseptic solution is used as a general antiseptic. it is used for the cleaning and disinfecting of wounds and the antiseptic treatment of burns.